Salute e Benessere

Innocan Pharma Granted First Patent in India for its Liposomal CBD Injection

This granted patent protects Innocan's synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), designed for precise dosing and sustained release of Synthetic CBD into the bloodstream. LPT-CBD received positive feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-IND meeting to advance its development as a non-opioid alternative for chronic pain management. The Indian patent, granted in a pharmaceutical market estimated at US $55 billion (Bain &…
PR Newswire
18/02/2025

Notice of Capital Markets Day - Save the Date

Louvain-la-Neuve, Belgium, 18 February, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will host a Capital Markets Day (CMD) for investors and analysts on Monday 7 April 2025 at 2pm CET / 1pm GMT / 8am ET. The event will include presentations, panel discussions and Q&A sessions led by IBA's management team with speakers from across the Group. Attendees will have the opportunity to gain valuable insights into IBA's strategy,...
Nasdaq GlobeNewswire
18/02/2025

Lutetium-177 (Lu-177) Market to Reach USD 5374 Million by 2030 | Rising Demand…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-4H13190/Global_Lutetium_177_Lu_177_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-4H13190/Global_Lutetium_177_Lu_177_Market Major Factors Driving the Growth of Lutetium-177 (Lu-177) Market : ● The Lutetium-177 market is poised for significant expansion as demand for targeted radiotherapy solutions increases in response to the global cancer burden, driven by...
PR Newswire
18/02/2025

Berlin Heals Holding AG Successfully Raises Over 7Million CHF Round for…

Berlin Heals Holding AG has already demonstrated the unprecedented success of its dilated cardiomyopathy therapy in a first-in-human pilot study. The company recently presented the Long-Term sustainable results of that study in a Late Breaking Clinical Trial session at the Technology and Heart Failure Therapeutics (THT) conference on February 11th in Boston and has plans to publish the results in an upcoming journal. Berlin Heals Holding AG has already demonstrated the unprecedented success…
PR Newswire
18/02/2025

Virtual Therapy Market to Reach USD 1.62 Billion by 2031: Growing Demand for…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-8G13643/Global_Virtual_Reality_Therapy_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-8G13643/Global_Virtual_Reality_Therapy_Market Major Factors Driving the Growth of Virtual Therapy Market: Unlock Insights: View Full Report Now!https://reports.valuates.com/market-reports/QYRE-Auto-8G13643/global-virtual-reality-therapy TRENDS INFLUENCING THE GROWTH OF...
PR Newswire
18/02/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 18 February 2025 at 16.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds increased on 17 February 2025 above (5) per cent of...
Nasdaq GlobeNewswire
18/02/2025

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the dosing of an additional four patients in its Intermediate Size Patient Population Expanded Access (ISPPEA) for patients with non-active secondary progressive multiple sclerosis (na-SPMS) who do not qualify for the ongoing Phase 2a study ( NCT06292923 )...
Nasdaq GlobeNewswire
18/02/2025

Michel Lussier Joins Caristo Diagnostics Board of Directors

"Michel is a highly respected leader whose deep technical expertise, executive experience and operational rigor make him a great addition to the Caristo board," said Oran Muduroglu, Chairman of Caristo Diagnostics. "Michel is a seasoned entrepreneur in the cardiology MedTech and Biotech industries with deep knowledge of science, clinical affairs, and go-to-market strategy, and execution. As a successful former CEO with a proven track record of creating shareholder value and…
PR Newswire
18/02/2025

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and…

Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rightsCollaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027Stoke to receive $165M upfront, shared...
Nasdaq GlobeNewswire
18/02/2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License…

®(aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness. The process to obtain regulatory approval is anticipated to be completed in the fourth quarter of 2025."We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan, Chief Scientific Officer of Alvotech. "Our success in developing…
Nasdaq GlobeNewswire
18/02/2025

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech's proposed biosimilar to Eylea ®(aflibercept), a biologic used to treat eye disorders, including...
Nasdaq GlobeNewswire
18/02/2025

LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of…

Dr David Reynolds, Chief Executive Officer of LoQus23 Therapeutics, commented: "Following our successful fundraise late last year, the Company is at a pivotal moment as we progress towards IND-enabling studies of our potent allosteric small molecule MSH3 inhibitor, part of the MutSβ complex. Cyrus brings a wealth of world class biotech expertise to guide us at this critical time and will help us to deliver treatments for patients with Huntington's and similar triplet repeat expansion…
PR Newswire
18/02/2025

HOOKII Revolutionizes Lawn Care in Europe: 3D LiDAR & Vision Fusion for Smarter…

"I live in a compact garden in France, and HOOKII 3D LiDAR technology made navigating around my flowerbeds and trampoline a breeze. Plus, the eco-friendly design fits perfectly with my sustainable lifestyle."— Luca Rossi, Early Adopter, France "I live in a compact garden inFrance, and HOOKII 3D LiDAR technology made navigating around my flowerbeds and trampoline a breeze. Plus, the eco-friendly design fits perfectly with my sustainable lifestyle."—Luca Rossi, Early…
PR Newswire
18/02/2025

VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough…

Previously, VIVOZON Pharmaceutical confirmed the safety and tolerance of the drug and secured statistical significance for efficacy in a domestic Phase 3 clinical trial and applied for new drug application (NDA) from MFDS in November 2023. The efficacy of the drug was confirmed through the primary endpoint Sum of Pain Intensity Difference over 12 Hours (SPID 12), and secondary endpoints including number of Patient-Controlled Analgesia (PCA) requests and opioid consumption over 12 Hours. ...
PR Newswire
18/02/2025

Enzymatica AB Year-end report 2024: Strong performance in core markets -…

• Earnings per share, basic and diluted, were SEK -0.05 (-0.09). • Earnings per share, basic and diluted, were SEK -0.05 (-0.09). • Cash flow from operating activities totaled SEK -20.6 million (-2.6). • Earnings per share, basic and diluted, were SEK -0.28 (-0.30). • Cash flow from operating activities for the period totaled SEK -60.5 million (-40.3). • Net cash totaled SEK 73.0 million (-17.7) at year-end. "Throughout the year, we have made significant...
PR Newswire
18/02/2025

Leqembi® sales reaches €200 million - first sales milestone achieved

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on February 18, 2025, at 08:00 CET. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, onFebruary...
PR Newswire
18/02/2025

CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline…

CJ Bioscience analyzed 500 metagenomic datasets from both IBD patients and healthy individuals and found that CJRB-201, the bacterial strain of Faecalibacterium, was significantly reduced in IBD patients compared to healthy individuals. Faecalibacterium is a key commensal bacterium in the gut, and its depletion has been closely linked to Crohn's disease and autoimmune disorders, making it a promising therapeutic target. CJ Bioscience analyzed 500 metagenomic datasets from both IBD patients…
PR Newswire
18/02/2025

Systemair nomination committee

It is hereby announced that after consultation between the company's three largest shareholders, ebm-papst AB has chosen to relinquish their seat on the nomination committee. The fourth largest shareholder Swedbank Robur Fonder has therefore been contacted. The nomination committee has been appointed to consist of the following persons: It is hereby announced that after consultation between the company's three largest shareholders, ebm-papst AB has chosen to relinquish their seat on the...
PR Newswire
18/02/2025

Basilea reports strong 2024 full-year results with significant increase in…

Total revenue increased by 32% to CHF 209m Operating profit tripled to CHF 61mOperating cash flow significantly increased to CHF 74m Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, February 18, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today its results for the financial year ended December 31, 2024...
Nasdaq GlobeNewswire
18/02/2025

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025…

Met 2024 growth targets for sales revenue (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 millionSubstantial clinical and regulatory progress in 2024, leading to multiple anticipated data readouts, product approvals and label extensions in 20252025 outlook reflects solid revenue growth and positive commercial cash flows to support strategic R&D investments with lower operating cash burn Saint-Herblain (France), February 18, 2025...
Nasdaq GlobeNewswire
18/02/2025

Press Release: Dupixent sBLA accepted for FDA priority review for the targeted…

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision expected by June 20, 2025Priority review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placeboBP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation...
Nasdaq GlobeNewswire
18/02/2025

Le Monde Gourmand Expands into the United Kingdom with LOOKFANTASTIC

"LOOKFANTASTIC is excited to launch Le Monde Gourmand, bringing the trending gourmand fragrance category to our customers at accessible prices, democratising access to premium-inspired scents and ensuring we cater to all fragrance lovers, regardless of budget." Frankie Whitehead, Senior Fragrance Buyer, LOOKFANTASTIC "LOOKFANTASTIC is excited to launch Le Monde Gourmand, bringing the trending gourmand fragrance category to our customers at accessible prices, democratising access…
PR Newswire
18/02/2025

Rznomics Inc. Liver Cancer Drug Candidate Secures Fast Track Designation

The Fast Track program, established by the FDA, supports the development of drugs for serious or life-threatening diseases by expediting the approval process. Once a drug is designated and if relevant criteria are met, it benefits from accelerated review and approval, as well as more frequent and flexible communication with the FDA. Additionally, during the Biologics License Application review, a rolling review can be conducted for each data section, providing an advantage in the evaluation…
PR Newswire
18/02/2025

Multiple System Atrophy Market Set to Experience Significant Growth with…

According to DelveInsight's estimates, in 2023, there were approximately 71,800 prevalent cases of MSA in the 7MM. Of these, the US accounted for 60% of the cases. According to the estimates, in 2023 there were around 56,600 nOH symptomatic cases of MSA in the 7MM. According to DelveInsight's estimates, in 2023, there were approximately71,800prevalent cases of MSA in the 7MM. Of these, the US accounted for60%of the cases. According to the estimates, in 2023 there were around56,600...
PR Newswire
17/02/2025
Altri  Comunicati